2021
article
Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life setting
Colin Deschanvres, Jacques Reynes, I. Lamaury, David Rey, Romain Palich, Firouzé Bani‐Sadr, Olivier Robineau, Claudine Duvivier, Laurent Hocqueloux, Lise Cuzin, Véronique Joly, François Raffi, André Cabie, Clotilde Allavena, C Chirouze, C. Drobacheff-Thiébaut, Adeline Foltzer, Kévin Bouiller, Laurence Mathieu, Quentin Lepiller, F Bozon, O Babre, A-S Brunel, Patrice Muret, É. Chevalier, Christine Jacomet, H. Laurichesse, O. Lesens, M. Vidal, Natacha Mrozek, C. Auméran, Olivier Baud, V. Corbin, E Goncalvez, Audrey Mirand, A Brebion, Cécile Henquell, Isabelle Fabre, Elodie Curlier, Rachida Ouissa, Cécile Herrmann‐Storck, B. Tressières, M. C. Receveur, F Boulard, Corinne Daniel, C Clavel, P.-M. Roger, Samuel Markowicz, N Chellum Rungen, Dominique Merrien, P Perré, Thomas Guimard, O Bollangier, S Léautez, Marine Morrier, L Laine, D Boucher, P Point, Laurent Cotte, Florence Ader, Agathe Becker, A. Boibieux, C. Brochier, Florence Brunel-Dalmas, O Cannesson, Pierre Chiarello, Christian Chidiac, S Degroodt, Tristan Ferry, Matthieu Godinot, J. M. Livrozet, Djamila Makhloufi, Patrick Miailhes, T. Perpoint, Melissa Perry, Cécile Pouderoux, Stanzi M. le Roux, Claire Triffault-Fillit, Florent Valour, Caroline Charre, V. Icard, J. C. Tardy, Mary‐Anne Trabaud, Isabelle Ravaux, A. Ménard, A Y Belkhir, Philippe Colson, C Dhiver, A Madrid, M Martin-Degioanni, Line Meddeb, Malika Mokhtarı, Anne Motte, A. Raoux, Christelle Tomei, Hervé Tissot‐Dupont, Isabelle Poizot‐Martin, Sylvie Brégigeon, Olivia Zaegel‐Faucher, Veronique Obry‐Roguet, Hélène Laroche, M Orticoni, M J Soavi, E. Ressiot, M J Ducassou, I Jaquet, S Galie, H Colson, A S Ritleng, A Ivanova, C. Debreux, C. Lions, T Rojas-Rojas, Sylvie Abel, J Bavay, B Bigeard, Ornella Cabras, R Dupin de Majoubert, Laurence Fagour, K Guitteaud, Athena Marquise, Fatiha Najioullah, S. Pierre-François, Jérémie Pasquier, Pierre-Yves Richard, Katherine De Rome, J M Turmel, C. Varache, N. Atoui, M Bistoquet, Éric Delaporte, Vincent Le Moing, Alain Makinson, N Meftah, Corinne Merle De Boever, Brigitte Montès, Ana Ferrer, Édouard Tuaillon, Benjamin Lefèvre, Eliette Jeanmaire, Sandrine Hénard, E. Frentiu, Alexandre Charmillon, Antoine Legoff, Nadine Tissot, Marie André, L. Boyer, M P Bouillon, M Delestan, François Goehringer, S Bevilacqua, Christian Rabaud, T. May, Olivier Aubry, Éric Billaud, Charlotte Biron, B. Bonnet, Sabelline Bouchez, David Boutoille, Cécile Brunet-Cartier, Benjamin Gaborit, A Grégoire, Matthieu Grégoire, Olivier Grossi, Romain Guéry, T Jovelin, Anne‐Marie Lefebvre, Paul Le Turnier, R. Lecomte, P Morineau, Véronique Reliquet, Solène Sécher, M Cavellec, E. Paredes, Alessandro Soria, Virginie Ferré, Elisabeth André‐Garnier, Audrey Rodallec, P Pugliese, S Bréaud, C Ceppi, David Chirio, Éric Cua, P. Dellamonica, Élisa Demonchy, Anne De Monte, J. Durant, C Etienne, Stephen J. Ferrando, R. Garraffo, C Michelangeli, V. Mondain, A. Naqvi, Nazan Tuna Oran, I. Perbost, M Carles, Christian Klotz, Christian Pradier, B Prouvost-Keller, Karine Risso, V Rio, Eric S. Rosenthal, Isabelle Touitou, S Wehrlen-Pugliese, G Zouzou, Thiérry Prazuck, C. Gubavu, Aymeric Sève, Susanna Giachè, V Rzepecki, M Colin, Cendrine Boulard, Gaëlle Thomas, Antoine Chéret, Cécile Goujard, Yann Quertainmont, Elina Teicher, Nathalie Lerolle, Stéphane Jauréguiberry, R Colarino, O Deradji, Antonio Arjona Castro, Aurélie Barrail‐Tran, Yazdan Yazdanpanah, Roland Landman, J. Ghosn, C. Rioux, Sylvie Lariven, A. Gervais, F.-X. Lescure, Sophie Matheron, Françoise Louni, Zélie Julia, Sylvie Le Gac, Charlotte Charpentier, Diane Descamps, Gilles Peytavin, Claire Aguilar, Fanny Alby‐Laurent, Karima Amazzough, Ghania Benabdelmoumen, P Bossi, G Cessot, Caroline Charlier, Paul‐Henri Consigny, Kaoutar Jidar, Emmanuel Lafont, Fanny Lanternier, J. Leporrier, Olivier Lortholary, Jérémie Lourenco, Perrine Parize, B. Pilmis, C. Rouzaud, F. Touam, M.A. Valantin, Roland Tubiana, Rachid Agher, Sophie Seang, L Schneider, Catherine Blanc, Christine Katlama, J L Berger, Yohan N’Guyen, D Lambert, I Kmiec, Maxime Hentzien, A. Brunet, Juliette Romaru, H Marty, Véronique Brodard, C. Arvieux, Pierre Tattevin, M Revest, Faouzi Souala, M. Baldeyrou, S. Patrat-Delon, J.-M. Chapplain, François Bénézit, Magali Dupont, Mélanie Poinot, Anne Maillard, Charlotte Pronier, F. Lemaı̂tre, Clément Morlat, M Poisson-Vannier, J P Sinteff, Amandine Gagneux‐Brunon, Élisabeth Botelho-Nevers, A. Frésard, V Ronat, F. Lucht, D. Rey, P Fischer, M Partisani, Geneviève Chêne, M. Priester, C Mélounou, Claudine Bernard-Henry, E de Mautort, Samira Fafi‐Kremer, Pierre Delobel, M Álvarez, N Biezunski, Alexa Debard, Cyrille Delpierre, Géraldine Gaube, P Lansalot, L Lelièvre, M Marcel, Guillaume Martin‐Blondel, M Piffaut, Lorena Porte, Karine Sauné, O. Robineau, F. Ajana, E Aïssi, I. Alcaraz, Enagnon Kazali Alidjinou, V. Baclet, Laurence Bocket, Anne Boucher, M Digumber, T. Huleux, B. Lafon-Desmurs, Agnès Meybeck, M Pradier, Macha Tétart, P. Thill, N. Viget, M. Valette
14Citations signalées, ce qui n’est pas une note de qualité
27Institutions déclarées
3Pays d’affiliation déclarés
Rattachement africain : fr, gp, mq.
Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Maintenance ART with dolutegravir-based dual regimens have proved their efficacy among HIV-1-infected subjects in randomized trials. However, real-life data are scarce, with limited populations and follow-up. OBJECTIVES: We assessed virological failure (VF) and resistance-associated mutations (RAMs) on dolutegravir maintenance regimens in combination with rilpivirine or with lamivudine or emtricitabine (xTC) and analysed the factors associated with VF. METHODS: Between 2014 and 2018, all HIV-1-infected adults included in the Dat'AIDS cohort and starting dolutegravir/rilpivirine or dolutegravir/xTC as a maintenance dolutegravir-based dual regimen were selected. VF was defined as two consecutive HIV RNA values >50 copies/mL or a single value >400 copies/mL. We compared cumulative genotypes before initiation of a maintenance dolutegravir-based dual regimen with genotype at VF. RESULTS: We analysed 1374 subjects (799 on dolutegravir/rilpivirine and 575 on dolutegravir/xTC) with a median follow-up of 20 months (IQR = 11-31) and 19 months (IQR = 11-31), respectively. VF occurred in 3.8% (n = 30) of dolutegravir/rilpivirine subjects and 2.6% (n = 15) of dolutegravir/xTC subjects. Among subjects receiving dolutegravir/rilpivirine, two genotypes harboured emerging RAMs at VF: E138K on NNRTI (n = 1); and E138K+K101E on NNRTI and N155H on INSTI (n = 1). Among subjects receiving dolutegravir/xTC, no new RAM was detected. The only predictive factor of VF on dolutegravir/rilpivirine was the history of failure on an NNRTI-based regimen (adjusted HR = 2.97, 95% CI = 1.28-6.93). No factor was associated with VF on dolutegravir/xTC. CONCLUSIONS: In this large real-life cohort, dolutegravir/rilpivirine and dolutegravir/xTC sustained virological suppression and were associated with a low rate of VF and RAM emergence. Careful virological screening is essential before switching to dolutegravir/rilpivirine in virologically suppressed patients with a history of NNRTI therapy.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life setting
- Date Crossref
- 15/10/2021
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Les institutions déclarées
Une affiliation ne permet pas de déduire la nationalité d’un auteur.
Les sujets associés
HIV/AIDS drug development and treatmentHIV Research and TreatmentHIV-related health complications and treatments